They specifically say that.
"EVT801 administered both as monotherapy and in combination with immuno-oncology therapies"
" It is hoped that administration of EVT801 may help to sensitise these tumours to immuno-oncology therapies such as Keytruda® (pembrolizumab) and Opdivo® (nivolumab) and thereby extend their use."
Ann: Kazia Corporate Presentation, page-11
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)